Search - tctmd.com

Displaying 1 - 20 of 37

Sort: Relevancy | Date

Top News in Coronary Artery Disease: 2018

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

Many PCI Patients Treated in China Have No Angina Symptoms

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

December 20, 2018

US and European DAPT Guidelines More Alike Than Different, Say Experts

News Daily News

US and European DAPT Guidelines More Alike Than Different, Say Experts

Yael L. Maxwell

December 03, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

August 28, 2018

MATRIX: 1-Year Results Confirm Superiority of Transradial PCI

News Conference News ESC 2018

MATRIX: 1-Year Results Confirm Superiority of Transradial PCI

Michael O'Riordan

August 25, 2018

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

Cancelled Cath Lab Activations and Timely Reperfusion: A ‘Balancing Act’

News Daily News

Cancelled Cath Lab Activations and Timely Reperfusion: A ‘Balancing Act’

Michael O'Riordan

August 21, 2018

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

News Daily News

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

August 17, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

Once Again, ISCHEMIA Trial Feels the Squeeze

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

CVD Prevention and Control Remains a Challenge in India

News Daily News

CVD Prevention and Control Remains a Challenge in India

June 26, 2018

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

News Daily News

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

Michael O'Riordan

June 07, 2018

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.